IMPEDIMED LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.078 AUD | 0.00% |
|
-2.50% | -46.21% |
| Apr. 30 | ImpediMed's Qaurterly Revenue Rises in Fiscal Q3; Shares Fall 8% | MT |
| Apr. 30 | Transcript : ImpediMed Limited, Q3 2024 Earnings Call, Apr 30, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -46.21% | 104M | C | ||
| +8.88% | 219B | B | ||
| +8.68% | 185B | B- | ||
| +14.25% | 135B | B- | ||
| +28.18% | 107B | A- | ||
| +14.65% | 51.28B | B+ | ||
| +4.48% | 51.01B | B+ | ||
| +4.39% | 41.85B | A | ||
| +7.00% | 37.02B | - | ||
| +26.06% | 31.27B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- IPD Stock
- Ratings ImpediMed Limited